Navigation Links
Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services
Date:12/1/2009

iCardiac now provides services to three out of top five global pharmaceutical companies.

Rochester, NY (PRWEB) December 1, 2009 -- iCardiac Technologies, Inc., a global leader in advanced cardiac core lab services and QT analysis, announced today that a top five pharmaceutical company has selected iCardiac as a preferred vendor of ECG core lab services. iCardiac will provide Highly Automated QT(sm) and Dynamic QT beat-to-beat(sm) service offerings in addition to all traditional ECG Core Lab services, including end-to-end study management, training, international equipment provision and deployment as well as scientific reporting.

"iCardiac continues to lead in the area of advanced cardiac safety solutions, dramatically improving study precision and reducing false positives and negatives,” said Sasha Latypova, Executive Vice President. "With the large number of project initiations and completions through 2008 and 2009, we are delighted with the accelerating speed of adoption for Highly Automated QT and Dynamic QT beat-to-beat in clinical trials.”

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives and high cost of the “gold standard” manual or semi-automated QT measurements has lead to efforts toward providing more advanced cardiac safety analytics.

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically-differentiated global cardiac core lab providing the industry’s most sophisticated ICH E14 compliant cardiac safety assessment methodologies for Phase I through Phase IV studies, supported by expert scientific consultation, end-to-end project management, worldwide site and equipment logistics, 24/7 customer support and regulatory data submission. iCardiac’s analysis services provide drug developers with more precise and cost-effective methods for ECG interval measurements, including Highly Automated QT, which is the market leading solution for automated evaluation of QT intervals for regulatory submissions. In addition, iCardiac provides Beyond QTsm, a suite of advanced ECG-based cardiac safety markers that have been accepted and used as a secondary end-point in regulatory approvals, and which delivers a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac’s COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/top_five_pharma/icardiac/prweb3272134.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. The MedZilla Report for August 2009 -- Health Care Grows Another 28,000 While Hospitals And Insurers Feel Painful Pinch
2. The first DFG research centers to be funded for another 4 years
3. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
4. OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
5. Cephalon Reports Another Strong Quarter
6. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
7. Diverse Coalition of Purchasers Respond to BIO CEO Fly-In: There is Another Side to The Story
8. Another industry first enabled by Benchmark Biolabs - Peros oral delivery platform and vaccine facility licensed by the USDA
9. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
10. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
11. Signalife Receives Another $3.3 Million Sales Orders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... USA (PRWEB) , ... May 23, 2017 , ... Federal ... as well as an enabler of life-saving medical and other vital technologies — deserves ... . They joined others in the scientific community today in responding to the President’s ...
(Date:5/23/2017)... ... May 23, 2017 , ... A recent survey conducted by the Weed Science ... control weed in 12 categories of broadleaf crops, fruits and vegetables, while common lambsquarters ... U.S. and Canada participated in the 2016 survey, the second conducted by WSSA. ...
(Date:5/23/2017)... ... May 22, 2017 , ... A new ... San Diego, California, this August will feature high-level speakers on quantum devices, graphene ... SPIE Optics and Photonics, the largest multidisciplinary optical sciences meeting in North America, ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Bacterial biofilms, surface ... molecules, can cause diverse pathologies ranging from food poisoning and catheter infections to gum ... is in the tens of billions of dollars per year, there is currently a ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):